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Abstract
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia with high
prevalence and human impact. Our aim was to perform a systematic review to find out
the extent of published research on TRS and to determine the current knowledge of TRS.
Studies were systematically collected using the databases of PubMed, Scopus and
CINAHL. English language original studies and reviews on TRS with most of the sample
including adults were included. The search located 449 studies. After abstract and
title review, 285 studies were included regarding definitions of TRS (N=11), genetics
(18), brain structure and functioning (18), cognition (8), other neurobiological
studies (16), medication (158), psychotherapy and cognitive rehabilitation (12),
electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation
(rTMS) (15), prognosis (21), and other miscellaneous studies (8) on TRS. Definitions
of TRS varied notably, and in most of the non-pharmacological studies the samples
were small. Based on limited evidence of genetics, brain structure and functioning and
cognition, TRS may present as a different disorder with different aetiology compared
to non-TRS. Regarding treatments, clozapine, olanzapine, risperidone, ECT and
cognitive-behavioural therapy have shown effectiveness, although the number of studies
and quality of research on interventions is limited. Very little is known about risk
factors, long-term course of illness and predictors of outcome in TRS, especially in
naturalistic samples. Our findings suggest that TRS is a poorly defined, studied and
understood condition considering its high prevalence, clinical and economic importance
and poor prognosis. To create a framework of knowledge for TRS, as a basis to develop
innovative studies on treatment, there is a need for a consensus on the definition of
TRS. In addition, prospective long-term studies and prognostic studies are needed.
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Introduction
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia and a common
condition faced by psychiatrists worldwide. One-fifth to one-third of all patients
with schizophrenia is considered to be resistant to treatment (4, 140). The burden of
TRS for the patients and to society is notably high (140). Patients experience
unfavourable events and comorbidity associated with the disease and treatment, and
unemployment and suicide risk are increased. Healthcare costs of TRS patients are 3 to
11-fold higher than schizophrenia patients in general (mainly due to high number of
hospitalizations), causing 60% to 80% of the total economic burden of schizophrenia.
Patients with early TRS signs and prior relapse (indicating TRS) have healthcare costs
up to 2.8 times higher than patients with early response to drug treatment and no
prior relapse (140). Correctly identifying and treating these patients could
contribute to reduce the burden on patients themselves, the economy and society.
In the original definition of TRS (10) the patient manifests a failure to respond to
three or more adequate trials of antipsychotic treatment within the last 5 years,
including medication from two distinct classes with dosing at least the equivalent of
1000mg per day of chlorpromazine. In addition, there must be at least moderately
severe continuous symptoms in certain psychosis symptoms (conceptual disorganization,
suspiciousness, hallucinatory behaviour and unusual thought content). Lastly, there
must be evidence of substantial current symptoms despite current optimized treatment
to which the patient is adherent: defined as a score of greater than or equal to 45 on
the Brief Psychiatric Rating Scale (BPRS) or 90 in the Positive and Negative Syndrome
Scale (PANSS) (10). Different definitions of TRS will be described later in this
article.
TRS may have some different biological features compared to treatment-responsive
schizophrenia, for example, less dopamine synthesis abnormalities and more marked
glutamatergic abnormalities (5, 7), reduced left dorsolateral prefrontal cortex (80),
genetic factors (49, 54) and higher rates of minor physical anomalies (95). TRS may
form a separable aetiological and diagnostic entity compared to schizophrenia in
general, as epidemiological study has recently suggested (159). Despite the public
health and human importance of TRS, it is a poorly studied and understood condition
and the research knowledge seems scattered. To our knowledge, there are no systematic
reviews summarizing scientific knowledge on several aspects of TRS, for example,
aetiology, risk factors, effective treatments and prognosis.
The aim of this study was to perform a systematic review to find out the extent of
published research on TRS and to determine the current knowledge of TRS.
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Methods
Data collection
A computerized literature search of articles on the topic was performed in April 2015,
and updated in April 2016, using electronic databases Scopus, PubMed (MEDLINE) and
CINAHL (EBSCO) by information scientist, one of the authors, NH. The systematic search
was implemented by using the following search strategy and algorithm to all databases:
((("ultra-resistant"[Title] OR "treatment-refractory"[Title] OR "treatment-resistant"
[Title])) AND schizophrenia [Title]) AND "English"[Language]. The search was restricted
to English language and there was no time restriction. We also did non-systematic
manual search from the included original articles.
Study selection
Search results were evaluated by two authors (AS, EJ) based on the titles and
abstracts of the articles. Additionally, the articles related to medication were
re-evaluated by AS and CM. The articles included were required to meet the following
criteria: original study or review (both systematic and non-systematic reviews were
included) on TRS, sample including mostly adult population and English language
article. The exclusion criteria were the following: conference abstract or letter or
book chapter, studies focusing only on childhood-onset schizophrenia and non-English
article.
Collected information
The included studies were grouped into the following categories based on their main
topic: definition of TRS, genetics, brain structure and functioning, cognition, other
studies on neurobiology, medication of TRS, psychotherapy and cognitive
rehabilitation, electroconvulsive therapy (ECT) and repetitive transcranial magnetic
stimulation (rTMS), prognosis and other miscellaneous studies. The number of original
studies and reviews in each of the categories were analysed. In addition, the main
results of each study topic were collected. It should be noted that in some cases the
articles were difficult to categorize into one category: if the article included
several topics of TRS. For this reason, the articles by Sinclair and Adams (116) and
Miyamoto et al. (109) were included in two categories (Medication of TRS and
Psychotherapy and cognitive rehabilitation). Studies analysing the efficacy of
medication were included into Medication of TRS, whereas studies focusing on
predictors of treatment response in TRS were categorized into Prognosis.
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Results
Search results
The literature search located 449 studies. All the article titles and abstracts were
reviewed and three articles from the manual search were added (49, 111, 159). After
this, 285 studies were included for further examination.
Figure 1. Flow chart of the selection of studies of treatment-resistant schizophrenia.
                      Records identified trough database
                                 searching
                                 (N=834)
                      Records after duplicates removed
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                                                               Records excluded by
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                         qualitative synthesis
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Study characteristics
The included studies were divided into ten groups based on their main topic (Table 1).
A total of 11 (4%) considered definitions of TRS, 18 (6%) genetics, 18 (6%) brain
structure and functioning, 8 (3%) cognition, 16 (6%) were other neurobiological
studies on TRS, 158 (55%) studies considered medication in TRS, 12 (4%) psychotherapy
and cognitive rehabilitation, 15 (5%) ECT and rTMS, 21 (7%) prognosis, and 8 (3%) were
other miscellaneous studies on TRS.
    Table 1. Number of included articles by the topic. 
  Topic                                         Total           Original        Reviews
                                                number          articles  
                                                of studies
  Definitions of TRS                            11              0               11
  Genetics and TRS                              18              17              1
  Brain structure and functioning in TRS        18              13              5
  Cognition in TRS                              8               7               1
  Other studies on neurobiology of TRS          16              12              4
  Studies on medication in TRS                  158             112             46
  Psychotherapy and cognitive
  rehabilitation in TRS                         12              7               5
  Electroconvulsive therapy (ECT) and
  repetitive transcranial magnetic
  stimulation (rTMS) in TRS                     15              13              2
  Prognosis of TRS                              21              18              3
  Other, miscellaneous studies on TRS           8               6               2
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What do we know about TRS?
Definition of TRS
The systematic search located 11 studies regarding the definition of treatment-resistant
schizophrenia (34-44). All of these studies were reviews.
The definition of TRS varies significantly depending on the source. Selected
definitions are presented in Table 2. The first and most used definition was created
by Kane and colleagues in 1988 (10). The Kane definition has been modified many times
since. In 2012 Suzuki et al. (24) systematically reviewed 33 studies of antipsychotic
medication, updated Kane’s definition and made their own proposal, described in Table 2.
The number of reviews and still lack of consensus since Kane’s first definition in
1988 implicate the difficulty of creating a standardized definition of TRS. In
comparison, WHO has produced, with an expert panel consensus, a definition for severe
asthma (2). However, the same problem occurs regarding treatment-resistant depression,
where there are no universally accepted criteria (30). Unfortunately, the varying
criteria for TRS complicate scientific studies and ultimately the treatment of TRS
patients.
Genetics and TRS
The systematic search located 18 studies on genetics and TRS. One of these was review
(48) and 17 were original studies (45-47, 49-62).
Genes are considered to take part in the development of TRS (49, 54, 57). Despite
there being a large number of genetic association studies regarding antipsychotic
response, there are only few studies that have compared TRS versus non-TRS (48). Frank
et al. (49) found higher polygenic risk score (based on the aggregate number of risk
loci previously identified from genome-wide association studies in schizophrenia
patients) among persons with a history of clozapine treatment (proxy for TRS) compared
to patients with no history of clozapine treatment. Persons with history of clozapine
treatment also displayed a significantly earlier age at onset and a higher frequency
of insidious disease onset. These results may suggest the existence of a more severe
and genetically based schizophrenia subgroup for which early intervention with
clozapine could be considered.
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_________________________________________________________________________________
    Table 2. Selected definitions of treatment-resistant schizophrenia (TRS).
________________________________________________________________________________________________________
  Definition                                              Referfence     Comment       
________________________________________________________________________________________________________
  At least three periods of treatment in the              Kane et al.    The first
  preceding five years with neuroleptic agents (from      1988 (10)      definition of TRS,
  at least two chemical classes at dosages                               and one of the
  equivalent to or greater than 1000mg/day                               most narrow
  chlorpromazine for a period of six weeks), each                        criteria
  without significant symptomatic relief AND
  No period of good functioning in the preceding
  five years AND
  Score of at least 45 and ≥4 in ≥2 of in the Brief
  Psychiatric Rating Scale (BPRS) psychotic items:
  conceptual disorganization, suspiciousness,
  hallucinatory behaviour, unusual thought content,
  and score of at least 4 in the Clinical Global
  Impression-Severity (CGI-S) AND
  No improvement after 6 weeks of treatment with
  haloperidol at up to 60mg or greater as measured
  by a reduction of at least 20% of the BPRS
  severity and CGI score.
________________________________________________________________________________________________________
  BPRS≥42 AND                                             Bitter et      One of the most
                                                          al. 2004 (I)   broad criteria
  Non-response to ≥1 first-generation antipsychotics                     for TRS
  (FGA) at 400-600mg for 4-6 weeks, because of
  either insufficient effectiveness or intolerable
  side effects
________________________________________________________________________________________________________
  At least two failed adequate trials with different      Suzuki et      Systematic review
  antipsychotics (at chlorpromazine-equivalent doses      al. 2012       of 33 trials
  of ≥600mg/day for ≥6 consecutive weeks) that could      (24)
  be retrospective or preferably include prospective
  failure to respond to one or more antipsychotic
  trials AND
  Both a score of ≥4 on the Clinical Global
  Impression-Severity (CGI-S) and a score of ≤49 on
  the Functional Assessment for Comprehensive
  Treatment of Schizophrenia (FACT-Sz) or ≤50 on the
  Global Assessment of Functioning (GAF) scales
________________________________________________________________________________________________________
Brain structure and functioning in TRS
The systematic search located 18 articles regarding brain structure and functioning in
treatment-resistant schizophrenia. Five of these articles were reviews (64, 67, 72,
73, 76) and 13 were original studies (63, 65, 66, 68-71, 74, 75, 77-80).
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Nakajima et al. (73) reviewed the neuroimaging findings in TRS (and
clozapine-resistant schizophrenia (CRS)). 25 studies were found, but only five studies
compared TRS patients to non-TRS patients. Existing studies did not show neuroimaging
correlates specifically to TRS or ultra-resistant schizophrenia (URS). Based on a
more recent systematic review by Mouchlianitis et al., (72) treatment-resistant and
treatment-responsive schizophrenia patients have differences in reductions of grey
matter and perfusion of frontotemporal regions, and increases in white matter and
basal ganglia perfusion. Clozapine treatment associated with reductions in caudate
nucleus volume. Based on the available evidence, some of the neurobiological changes
seen in TRS lie along a continuum with treatment-responsive schizophrenia, whereas
other differences are categorical in nature and have potential to be used as
biomarkers. However, further replication is needed, and for neuroimaging findings to
be clinically translatable, future studies need to focus on a priori hypotheses and be
adequately powered.
Non-TRS patients showed higher striatal dopamine functions than TRS patients and
healthy volunteers, and there were higher glutamatergic levels in TRS in comparison
with responders (65). Regarding connectivity, TRS patients showed reduced connectivity
between ventral striatum and substantia nigra, and corticostriatal connectivity was
more disturbed in TRS compared to non-TRS (79).
If differences in brain structure and functioning in TRS compared to non-TRS would be
found it might also explain the efficacy and exact mechanism of clozapine, which is
presently rather unknown. In the future, the research of the glutamatergic system
could provide useful information in neuroimaging studies focused on the frontal
cortical-basal ganglia-thalamic circuits. Precise definition of TRS is crucial for the
future success of the research, and for the correct subtyping of study subjects into
different subtypes based on the treatment response (72, 73).
Cognition in TRS
The systematic search located eight articles considering cognition in TRS. One (88) of
these articles was a review and seven were original studies (81-87). Based on these,
our knowledge of cognition in TRS in contrast to non-TRS is still very weak.
Frydecka et al. (83) compared cognitive performance between 53 TRS and 32 non-TRS
patients. Cognitive deficits were more robust in TRS patients than in non-TRS subjects
in several domains of cognition. In 19 TRS and 22 non-TRS patients, TRS patients had
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poorer cognition and exhibited higher symptoms. Poorer cognitive performance
correlated with more severe negative symptoms in TRS but not in non-TRS patients (82).
Also non-significant results exist. There were no differences in cognitive functioning
in 16 non-TRS patients, 20 TRS patients responding to clozapine monotherapy and 15 CRS
patients responding to antipsychotic polypharmacy (81).
Other studies on neurobiology of TRS
The systematic search located 16 articles on other studies on neurobiology of TRS.
Four of these studies were reviews (89, 90, 98, 101) and 12 were original articles
(91-97, 99, 100, 102-104). The studies considered hormones, receptor functions and
inflammation in TRS, for example.
Studies on medication in TRS
Antipsychotic drugs relieve symptoms and prevent relapses, but have limited efficacy
particularly on negative and cognitive symptoms, and have neurological and metabolic
side effects. In antipsychotic treatment, really innovative improvements, or
breakthroughs in terms of new molecules or medication algorithms, have not been made
during the last 20 years. Leucht et al. (13) analysed 212 suitable trials analysing
the efficacy of antipsychotics in schizophrenia, and included altogether 43,049
participants. As a result, all drugs were significantly more effective than placebo.
Different antipsychotics differed substantially in side effects, and small but robust
differences were seen regarding efficacy.
Our systematic search located 158 individual articles on medication in TRS (references
on request from the corresponding author). 46 of these were reviews and 112 were
original articles. The number of double-blind randomized controlled trials (RCT), i.e.
gold standard in analysing effectiveness of medication, is surprisingly low regarding
TRS (14).
Clozapine has been considered as the most effective drug for patients with TRS,
although new criticism for the evidence has been raised (18). The meta-analysis by
Chakos et al. (3) compared the effectiveness of clozapine (CLZ) and first-generation
antipsychotics (FGA) in 6 double-blind randomized controlled trials. They found a
moderate overall effect in favour of clozapine. The meta-analysis by Chakos et al. (3)
compared the effectiveness of CLZ and risperidone in two studies. They did not find
differences in response rate. The meta-analysis by Souza et al. (23) compared the
efficacy of CLZ and olanzapine in seven studies (5 efficacy trials, one safety trial
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and one imaging study), and found more improvement on PANSS negative and positive
subscales for the CLZ group. Based on very recent network meta-analysis by Samara et
al. (18) on blinded RCT in TRS, superiority was found for olanzapine, clozapine, and
risperidone compared to other antipsychotics in various efficacy outcomes in TRS,
though the results were not consistent and the effect sizes were small. Though more
effective than first-generation antipsychotics, rather surprisingly, there was no
support for the superiority of clozapine to other second-generation antipsychotics
(18).
In these meta-analyses, as in some other studies on the efficacy of antipsychotic
drugs on TRS, the problem is that some samples have not been clearly defined using the
operational criteria of TRS, i.e. at least part of the sample may not meet the clear
definition of TRS. For example, studies may define "TRS population" just as "patients
with residual positive and negative symptoms". An overly heterogeneous sample may be
one reason why it has been difficult to ascertain the effectiveness of clozapine and
some other antipsychotics, therefore a future focus on an operational definition of
the TRS population might be one solution to change the current evidence (18).
Although these results regarding clinical work are rather confusing, Kane and Correll
(9) made an important note: in the meta-analysis by Samara et al. (18), studies
showing a superiority of clozapine were all open-label studies, whereas the blinded,
randomized studies failed to show a difference. The fact that the studies with
positive results in favour of clozapine were unblinded, mostly nonrandomized, could be
interpreted in two ways the positive findings are caused by bias of treating
clinicians, patients and/or raters, or, interestingly, the patients in open studies
are more representative of the severely ill patients (i.e. truly TRS patients) who
benefit most from clozapine, but are less likely to enrol in complex and demanding
RCT. Despite somewhat confusing evidence, in clinical practice we need tested
treatment algorithms for medication in TRS. At the moment, there is also evidence for
clozapine from large, naturalistic register studies (17, 19). There are studies
suggesting that clozapine should be offered to TRS patients earlier in their illness
(19). This could potentially also lower an increased suicide rate in schizophrenia
(6).
About 40% to 70% of TRS cases do not respond to clozapine. This condition is
considered as clozapine-resistant schizophrenia (CRS), super-refractory schizophrenia
or ultra-resistant schizophrenia (10, 109). According to a recent review (109),
clozapine augmentation strategies that have at least grade B of category of evidence
and have more than one trial are: 1) adding other antipsychotic drug, or 2) adding
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lamotrigine (28), or 3) adding electroconvulsive therapy. There are no strategies with
grade A of category of evidence. Other augmentations such as topiramate,
tetrabenazine, five glutamatergic drugs, including CX516, D-cycloserine, D-serine,
glycine, and sarcosine, and fluoxetine and mirtazapine have inconsistent results or
negative evidence (grade D or E of category of evidence).
Despite the massive body of research on antipsychotics and many studies on TRS, to our
knowledge, there are no studies on guided discontinuation of antipsychotics in TRS,
nor optimal dose or dose tapering. In somatic medicine (e.g. geriatrics and oncology),
medication is usually discontinued when its effects are minimal and harms are larger.
Such studies or guidelines do not exist in TRS.
Psychotherapy and cognitive rehabilitation in TRS
The systematic search located 11 articles considering psychotherapy and one article on
cognitive rehabilitation in TRS (111). Five of these studies were reviews (106, 108,
109, 113, 116) and seven were original articles (105, 107, 110-112, 114, 115).
Ranasinghe and Sin (113) systematically reviewed the studies on augmenting clozapine
with psychosocial intervention. Research on augmenting clozapine with psychosocial
interventions is scarce. Two trials of clozapine augmentation with cognitive
behavioural therapy (CBT) showed as having positive effects on overall mental state.
CBT adjunctive therapy is superior to the befriending control group in reducing
psychotic symptoms and general psychopathology for up to 6 months at follow-up. One
trial on occupational therapy, clozapine augmentation (107), suggested that the
therapy significantly improved occupational performance and interpersonal
relationships in 3 and 6 months follow-up.
In one randomized study, TRS patients having cognitive rehabilitation showed
significantly greater improvements at 3 months in cognition, positive symptoms,
functioning and insight, compared to patients participating in the occupational
therapy group (111).
ECT and rTMS in TRS
The systematic search located 15 studies considering ECT (117-130) or rTMS (131) in
TRS. Two of these studies were review articles (117, 126) and 13 original studies
(118-125, 127-131).
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There is no consensus on the role of ECT in the treatment or maintenance treatment of
TRS. Chanpattana and Andrade (117) suggest that the combination of ECT and
antipsychotic drugs have positive effects on some patients with TRS who did not
respond to the sole treatment of medication. The treatment is more effective as a
combination than separate. The long-term benefits of ECT and the specific effects and
mechanisms of the treatment are still unknown.
Lally et al. (126) analysed in their very recent meta-analysis the proportion of
responders to clozapine + ECT in TRS in RCT and open-label trials. There were
altogether 71 people with TRS, who underwent clozapine + ECT in 4 open-label trials
(N=32) and in 1 RCT (N=39). The proportion of response to clozapine + ECT was 54%.
The data suggests that ECT may be an effective and safe clozapine augmentation strategy
in TRS, however further research is needed before ECT can be included in standard TRS
treatment algorithms (126).
There were no significant differences in cognition after combined ECT and
antipsychotic therapy in TRS patients, suggesting that combined electroconvulsive
therapy may not have a negative influence on the neuropsychological functioning of
patients with treatment-resistant schizophrenia. The sample size of the study was 27
patients diagnosed with TRS, with 14 men and 13 women (127, 128).
In the only rTMS study, rTMS of the left temporo-parietal region (N=12) was more
effective than bilateral rTMS (N=12) or placebo (N=12) in reducing auditory
hallucinations in schizophrenia patients with medication-resistant auditory verbal
hallucinations (131).
Prognosis of TRS
The systematic search located 21 studies regarding prognosis of TRS. Three of these
studies were reviews (133, 140, 148) and 18 were original articles (132, 134-139,
141-147, 149-152). Most of these concerned treatment response as an outcome, and very
little is known about other outcomes (such as occupational capacity, social remission)
and long-term course of illness.
About 40% to 70% of TRS patients have an unfavourable prognosis (as measured by
non-response to clozapine) (140). TRS patients are often unemployed and have an
increased suicide risk compared to schizophrenia patients in general. TRS patients
also have high rates of smoking (56%), alcohol abuse (51%) and substance abuse (51%)
(140).
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In a very recent study (132), 51% of 78 discharged (from specialized inpatient
treatment for TRS) patients continued to live in the community at one-year follow-up.
Severe negative symptoms, especially anhedonia/asociality, were a significant
predictor of shorter post-hospital community tenure. Neurocognitive impairment and
positive symptoms did not predict community outcome.
Younger age, shorter duration of illness before clozapine treatment, and fewer
antipsychotic trials before the use of clozapine associated with a better response to
clozapine (152). These results suggest that reducing the delay for starting clozapine
may increase the effectiveness of clozapine in TRS.
Other, miscellaneous studies on TRS
The systematic search located eight articles (153-160) which did not focus
specifically on any of the categories previously mentioned.
Two of these studies were original articles on risk factors of TRS compared to
non-TRS. In a Danish population-based study utilizing national registers, 21% of 8044
patients fulfilled the main proxy definition of TRS during a median follow-up of 9
years. Younger age, living in a rural or less urban area, primary education level,
more psychiatric hospital treatment days in the year before first schizophrenia
diagnosis, inpatient at first schizophrenia diagnosis, paranoid subtype, comorbid
personality disorder and previous suicide attempt were all significantly associated
with TRS (159).
Yamanaka et al. (160) analysed how background and risk factors associate with TRS
status (compared to non-TRS) during different phases of illness. At first-episode
psychosis, lower age at onset, shorter duration of untreated psychosis, lower
antipsychotic dosages and receiving ECT more often associated with TRS status. After
first episode, dopamine supersensitivity psychosis (DSP), deficit syndrome, higher
symptom severity and higher antipsychotic dosages associated with TRS status. Of all
these factors, DSP and deficit syndrome were the strongest predictors of TRS.
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Discussion
Main results
There are relatively many publications on TRS, though the number is small compared to
the number of publications on schizophrenia in general (46,394 hits in April 2016 from
PubMed with search algorithm schizophrenia [Title] AND "English"[Language]). However,
regarding specific topics, e.g. epidemiology, prognosis, aetiology, the number of
studies is surprisingly low. There are several definitions of TRS, without an
internationally accepted consensus of definition. The number and quality of studies on
medication and other treatments of TRS are surprisingly low. Based on the limited
evidence on genetics, brain structure and functioning and cognition, TRS may present a
different disorder with a different aetiology compared to non-TRS. Our findings
suggest that TRS is a poorly studied and understood condition, considering its high
prevalence, clinical importance and poor prognosis.
Finnish studies on TRS
In Finland, the studies on TRS have focused mostly on medication (16), especially
clozapine (8, 31-33) and a combination of clozapine and another drug (25-27). Also
factors relating to clozapine concentration and efficacy have been of interest, e.g.
genetics (12) and smoking (20), adverse effects of clozapine (20-22, 29) and factors
associated with metabolism in clozapine-treated patients (11). There is also one study
on pregnancy, delivery, and socio-demographic precursors of clozapine treated
schizophrenia patients (proxy for TRS) (15).
Clinical implications
Despite the number of trials, we know surprisingly little about efficacy of drugs in
TRS. The major pitfalls of the studies are small sample size, heterogeneity of study
samples due to lax or unclear eligibility criteria, and doubtful clinical usefulness
of the term "response" (14). Despite this, in clinical practice we need to do our best
for the treatment of the patients. Regarding medication, clozapine, olanzapine, and
risperidone have had efficacy in various outcomes (18). The number of studies on
psychosocial treatment is low. In addition, there is only one study on a promising
treatment option for schizophrenia, cognitive remediation (111).
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Based on naturalistic samples, markers of TRS already show at the beginning of illness
(159, 160). Special focus could be paid to schizophrenia patients with a younger age
at onset, more severe illness course at the beginning of the illness, the presence of
personality disorder and suicidality (159), and those with psychotic relapses and
deficit syndrome during the illness course (160). On the other hand, there may be a
group of later TRS patients showing short duration of untreated psychosis and having
smaller doses of antipsychotic medication at first episode (160). All these findings
are based on just a few studies and should be considered with caution. However, based
on these findings we should do our best to individually and actively treat, monitor
and follow-up the patients.
Implications for future studies on TRS
In the future, first, we need a consensus of the definition of TRS. Over the years,
different time periods, needs and hypotheses may have been affecting the development
of the definition of TRS. In addition, the definition of TRS in trials will impact on
what kind of indication the analysed drug compound will receive. In order to
understand the mechanism of TRS we need well-defined groups, and if still too
heterogeneous, then data-driven stratification should be considered. Since we still do
not have a good understanding of TRS as a process, we are unable to find aetiology and
effective treatments for TRS.
Trials should be designed with stringent and clear eligibility criteria that properly
define the patient’s profile. With this it would then be easier to translate the
results into clinical practice and to specific populations such as TRS and
clozapine-resistant schizophrenia (CRS).
Studies on epidemiology, i.e. prevalence, risk factors, course of illness in TRS, with
years of follow-up are needed. Predictors of response and non-response in TRS and new
treatment options for TRS should be explored. Large naturalistic and register-based
samples are especially needed. Another important limitation of TRS studies is that
they do not differentiate TRS with negative syndrome from TRS with positive syndrome.
which are assumed to have different neurobiological basis. In the future this aspect
should be considered as well.
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Strengths and limitations
This is the first systematic review of all aspects of TRS. We used several electronic
databases and all the abstracts were analysed by two authors, which can be considered
as strengths of this study.
We did not use term clozapine in the search algorithm. To decrease the needed
resources, we excluded studies focusing only on childhood schizophrenia, and we
restricted our search to English language articles.
Conclusions
TRS is a poorly defined, studied and understood condition considering its clinical and
economic importance and often poor prognosis. There is a need for a consensus on the
definition of TRS, this being the first step towards better quality studies and better
comparability and understanding of this important condition. There is also a need for
longitudinal and prognostic studies and innovative treatments for TRS.
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